Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.58 |
| ▸ | CTSL | P07711 | 5/20 | 0.57 |
| ▸ | CTSS | P25774 | 5/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CTSB | P07858 | 4/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348791 | 1.00 | PPARG (0.71) | PPARGOPRK1CTSLCTSSATM | |
| SCHEMBL8353576 | 0.86 | OPRK1 (0.64) | PPARGOPRK1CTSLCTSSATM | |
| SCHEMBL14626518 | 0.83 | PPARG (0.53) | PPARGOPRK1CTSLCTSSATM | |
| SCHEMBL3255270 | 0.82 | ATM (0.60) | PPARGOPRK1CTSLCTSSATM | |
| SCHEMBL3255265 | 0.82 | ATM (0.60) | PPARGOPRK1CTSLCTSSATM | |
| SCHEMBL16215928 | 0.79 | ATM (0.69) | PPARGOPRK1CTSLCTSSATM | |
| SCHEMBL13168601 | 0.79 | ATM (0.69) | PPARGOPRK1CTSLCTSSATM | |
| SCHEMBL13979588 | 0.79 | CTSL (0.67) | PPARGOPRK1CTSLCTSSATM | |
| SCHEMBL1362502 | 0.79 | ATM (0.77) | PPARGOPRK1CTSLCTSSATM | |
| SCHEMBL3255533 | 0.79 | ATM (0.77) | PPARGOPRK1CTSLCTSSATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160902-B2 | Amide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160902-B2 | Amide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| WO-2005049564-A1 | AMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050107355-A1 | Amide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107355-A1 | Amide derivatives and methods of their use | HRH2, SLC10A2, ALPI | PPARG 356/4885OPRK1 16/4885CTSL 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.